Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature
- 11 November 2018
- journal article
- review article
- Published by Springer Nature in Child's Nervous System
- Vol. 35 (1) , 83-89
Abstract
Nimotuzumab is an IgG1 antibody that targets epidermal growth factor receptor (EGFR). Overexpression of EGFR is detected in some pediatric brain tumors including diffuse intrinsic pontine gliomas (DIPG)s.Keywords
This publication has 18 references indexed in Scilit:
- Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhoodJournal of Neuro-Oncology, 2014
- Morphologic Characteristics and Immunohistochemical Profile of Diffuse Intrinsic Pontine GliomasAmerican Journal of Surgical Pathology, 2013
- Management of Diffuse Pontine Gliomas in Children: Recent DevelopmentsPediatric Drugs, 2013
- A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi methodNeuro-Oncology, 2013
- Pediatric diffuse intrinsic pontine glioma patients from a single centerChild's Nervous System, 2012
- Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biologyCancer Treatment Reviews, 2012
- Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experienceJournal of Neuro-Oncology, 2011
- Nimotuzumab for pediatric diffuse intrinsic pontine gliomasExpert Opinion on Biological Therapy, 2010
- Whole-Genome Profiling of Pediatric Diffuse Intrinsic Pontine Gliomas Highlights Platelet-Derived Growth Factor Receptor α and Poly (ADP-ribose) Polymerase As Potential Therapeutic TargetsJournal of Clinical Oncology, 2010
- Diffuse brainstem glioma in children: critical review of clinical trialsThe Lancet Oncology, 2006